CN113166729A - 过表达aoah的基因工程间充质干细胞及其用途 - Google Patents

过表达aoah的基因工程间充质干细胞及其用途 Download PDF

Info

Publication number
CN113166729A
CN113166729A CN201980071846.5A CN201980071846A CN113166729A CN 113166729 A CN113166729 A CN 113166729A CN 201980071846 A CN201980071846 A CN 201980071846A CN 113166729 A CN113166729 A CN 113166729A
Authority
CN
China
Prior art keywords
leu
msc
aoah
mscs
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980071846.5A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·卡拉汉
雪莉·H·J·梅
王琰
玛丽亚·弗洛里安
凯特琳·罗
李乾彰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ottawa Health Research Institute
United Therapeutics Corp
Original Assignee
Ottawa Health Research Institute
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ottawa Health Research Institute, United Therapeutics Corp filed Critical Ottawa Health Research Institute
Publication of CN113166729A publication Critical patent/CN113166729A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01077—Acyloxyacyl hydrolase (3.1.1.77)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980071846.5A 2018-10-29 2019-10-29 过表达aoah的基因工程间充质干细胞及其用途 Pending CN113166729A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752000P 2018-10-29 2018-10-29
US62/752,000 2018-10-29
PCT/CA2019/051526 WO2020087160A1 (en) 2018-10-29 2019-10-29 Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof

Publications (1)

Publication Number Publication Date
CN113166729A true CN113166729A (zh) 2021-07-23

Family

ID=70462996

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980071846.5A Pending CN113166729A (zh) 2018-10-29 2019-10-29 过表达aoah的基因工程间充质干细胞及其用途

Country Status (10)

Country Link
US (1) US20220010281A1 (enExample)
EP (1) EP3874029B1 (enExample)
JP (1) JP7372982B2 (enExample)
KR (1) KR20210086662A (enExample)
CN (1) CN113166729A (enExample)
AU (1) AU2019370629A1 (enExample)
ES (1) ES2962812T3 (enExample)
IL (1) IL282820A (enExample)
SG (1) SG11202103509RA (enExample)
WO (1) WO2020087160A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021360131A1 (en) * 2020-10-16 2023-05-25 Ottawa Hospital Research Institute Cell-based therapy for viral diseases
CN116570711A (zh) * 2022-12-21 2023-08-11 上海交通大学医学院附属第九人民医院 酰基羧酸水解酶在制备治疗肾脏纤维化疾病的药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101378764A (zh) * 2005-12-09 2009-03-04 贝勒研究院 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
CN102459638A (zh) * 2009-06-19 2012-05-16 默克专利有限公司 用于测定抗egfr抗体在癌症治疗中的功效的生物标记和方法
CN104284979A (zh) * 2012-03-27 2015-01-14 库瑞瓦格有限责任公司 用于提高的蛋白或肽表达的人工核酸分子
US20170151284A1 (en) * 2014-06-30 2017-06-01 Tigenix S.A.U. Mesenchymal stromal cells for treating sepsis
CN107208063A (zh) * 2015-01-08 2017-09-26 埃普塞斯有限责任两合公司 表达α‑1抗胰蛋白酶（AAT）的遗传修饰的间充质干细胞

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US5281520A (en) * 1990-09-12 1994-01-25 Zymogenetics, Inc. Method for producing acyloxyacyl hydrolase
AU2009275135A1 (en) * 2008-07-21 2010-01-28 Compugen Ltd. Angiopoietin derived peptides
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
EP2626369A1 (en) * 2011-11-24 2013-08-14 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Engineered mesenchymal stem cells and their therapeutic use
WO2013151663A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
AU2014342162B2 (en) * 2013-11-01 2020-01-02 Regeneron Pharmaceuticals, Inc. Angiopoietin-based interventions for treating cerebral malaria
EP3087101B1 (en) * 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
JP7269733B2 (ja) * 2015-06-12 2023-05-09 レンティジェン・テクノロジー・インコーポレイテッド 操作されたｔ細胞を用いて癌を処置するための方法
EP3351254A4 (en) * 2015-09-15 2019-07-17 Kangstem Biotech Co., Ltd. COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES WITH SOD3 OVEREXPRIMATING STEM CELLS AS AN ACTIVE SUBSTANCE

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101378764A (zh) * 2005-12-09 2009-03-04 贝勒研究院 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
CN102459638A (zh) * 2009-06-19 2012-05-16 默克专利有限公司 用于测定抗egfr抗体在癌症治疗中的功效的生物标记和方法
CN104284979A (zh) * 2012-03-27 2015-01-14 库瑞瓦格有限责任公司 用于提高的蛋白或肽表达的人工核酸分子
US20170151284A1 (en) * 2014-06-30 2017-06-01 Tigenix S.A.U. Mesenchymal stromal cells for treating sepsis
CN107208063A (zh) * 2015-01-08 2017-09-26 埃普塞斯有限责任两合公司 表达α‑1抗胰蛋白酶（AAT）的遗传修饰的间充质干细胞

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER D. PORADA ET AL.: "Mesenchymal Stem Cells as Therapeutics and Vehicles for Gene and Drug Delivery", ADV DRUG DELIV REV., vol. 62, no. 12, 30 September 2010 (2010-09-30), pages 1, XP027509884, DOI: 10.1016/j.addr.2010.08.010 *
NATHAN M. NOVOTNY ET AL.: "ANGIOPOIETIN-1 IN THE TREATMENT OF ISCHEMIA AND SEPSIS", NATHAN M. NOVOTNY ET AL., vol. 31, no. 4, 31 December 2009 (2009-12-31), pages 335, XP055706705, DOI: 10.1097/SHK.0b013e3181862c63 *
NOREDIA OJOGUN ET AL.: "Overproduction of acyloxyacyl hydrolase by macrophages and dendritic cells prevents prolonged reactions to bacterial lipopolysaccharide in vivo", J INFECT DIS, vol. 200, no. 11, 31 December 2009 (2009-12-31), pages 2, XP055706704, DOI: 10.1086/646616 *
李娟 等: "基因芯片在筛查儿童过敏性紫癜差异基因中的研究", 江西医药, vol. 51, no. 10, 20 October 2016 (2016-10-20), pages 991 - 995 *

Also Published As

Publication number Publication date
WO2020087160A1 (en) 2020-05-07
JP2022513379A (ja) 2022-02-07
AU2019370629A1 (en) 2021-05-20
EP3874029A1 (en) 2021-09-08
IL282820A (en) 2021-06-30
SG11202103509RA (en) 2021-05-28
US20220010281A1 (en) 2022-01-13
EP3874029A4 (en) 2022-08-03
EP3874029B1 (en) 2023-08-30
CA3116196A1 (en) 2020-05-07
KR20210086662A (ko) 2021-07-08
JP7372982B2 (ja) 2023-11-01
ES2962812T3 (es) 2024-03-21

Similar Documents

Publication Publication Date Title
KR101992807B1 (ko) 조직 재생을 유도하기 위한 펩티드 및 그의 이용
JP5750600B2 (ja) 免疫原性ペプチドおよび免疫障害におけるその使用
AU2017237912B2 (en) Methods of treating mitochondrial disorders
JP2023052475A (ja) リソソーム障害を治療する方法
US20110097309A1 (en) Pharmaceutical Agent for Promoting the Functional Regeneration of Damaged Tissue
Leblond et al. Developing cell therapy techniques for respiratory disease: intratracheal delivery of genetically engineered stem cells in a murine model of airway injury
JP6750782B2 (ja) 移植用幹細胞及びその製造方法
JP5706821B2 (ja) ペリオスチンに誘導される膵臓再生
JP7372982B2 (ja) Ａｏａｈを過剰発現する遺伝子組換え間葉系幹細胞及びその使用
WO2003014340A2 (en) Human histone deacetylase-related gene and protein hdac10
CA3116196C (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
JP2024522256A (ja) 免疫寛容を誘導するための合成タンパク質
HK40057211B (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
HK40057211A (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
US20040241807A1 (en) Interleukin-1 related gene and protein
CN116888260A (zh) 病毒性疾病的基于细胞的疗法
JP2023549077A (ja) シュードタイプ粒子、改変細胞、関連組成物、及び関連方法
Pagès et al. Developing cell therapy techniques for respiratory disease: Intratracheal delivery of genetically engineered stem cells in a murine model of airway injury
HK40016634A (en) Methods of treating lysosomal disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210723

RJ01 Rejection of invention patent application after publication